Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of oral BG2109 with or without add-back therapy for heavy menstrual bleeding associated with uterine fibroids in premenopausal women
CTR20221747Phase 3Terminated
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linzagolix in Fibromyoma (LM), menstrual disorders, sponsored by Kissei Pharmaceutical Co., Ltd.. Started Dec 2022; status: terminated.
02
Drugs
linzagolix
03
Conditions
Fibromyoma (LM)menstrual disorders
Beyond the preview
Go deeper on CTR20221747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221747.